ArticleScientific reports2026
Green silver nanoparticles of Khaya senegalensis as dual inhibitors of viral thymidine kinase and 3 C protease: metabolomics, and computational insights.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To the best of our knowledge, this is the first study to evaluate green synthesized silver nanoparticles loaded Khaya senegalensis (Desr.) A. Juss. against HSV-1 and Coxsackie B4, while providing mechanistic insights through enzyme inhibition and in silico analyses. FTIR, HRTEM, UV–visible spectroscopy, particle size, and zeta potential analyses further characterized the nanoparticles, which exhibited colloidal stability (− 20.7 ± 5.26 mV), predominantly spherical morphology, and a core size of 8–38 nm by HRTEM. The larger hydrodynamic diameter observed by DLS (~ 463 nm) reflects the core plus capping biomolecules and solvation layer, consistent with effective nanoparticle stabilization. KS-AgNPs leaves showed the strongest antiviral effect against HSV-1 and Coxsackie B4, with an IC₅₀ of 99.65 ± 1.84 µg/mL. This was better than the crude leaf extract (116.26 ± 1.28 µg/mL) but less potent than the standard drug acyclovir (79.25 ± 0.14 µg/mL). Metabolomic profiling identified thirty secondary metabolites, with molecular docking and dynamics highlighting myricetin as a key antiviral compound (binding energies: −10.98 kcal/mol for thymidine kinase, − 9.42 kcal/mol for 3 C protease). Furthermore, pharmacokinetics, and ADME studies for myricetin was performed. In vitro enzyme inhibition assays confirmed suppression of thymidine kinase (IC₅₀ = 0.249 ± 0.007 µg/mL) and 3 C protease (IC₅₀ = 0.732 ± 0.028 µg/mL). The results indicate that biogenic KS-AgNPs have notable antiviral effects, and that metabolites from Khaya senegalensis may serve as potential candidates for future antiviral therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.